Protective effects of lactoferrin in Escherichia coli-induced bacteremia in mice: Relationship to reduced serum TNF alpha level and increased turnover of neutrophils

Inflammation Research

Volumn 53, Issue 7, 2004, Pages 292-2296

  Zimecki, M ^a   Artym, J ^a   Chodaczek, G ^a   Kocieba, M ^a   Kruzel, M L ^b  

^a INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Bacteremia; Lactoferrin; Neutrophils; TNF alpha

Indexed keywords

INTERLEUKIN 1; LACTOFERRIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTEREMIA; BIOASSAY; BLOOD SMEAR; BONE MARROW; CELL LINEAGE; CIRCULATION; CONTROLLED STUDY; DOWN REGULATION; ESCHERICHIA COLI; FEMALE; GIEMSA STAIN; HISTOLOGY; LEUKOCYTE COUNT; MOUSE; NEUTROPHIL; NONHUMAN; PROMYELOCYTE; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; SEPSIS;

EID: 3242762938     PISSN: 10233830     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00011-004-1257-1     Document Type: Article

References (45)

1. Hazinski MF, Iberti TJ, Mac Intyre NR, Parker MM, Tribett D, Prion S et al. Epidemiology, pathophysiology and clinical presentation of Gram-negative sepsis. Am J Crit Care 1993; 2: 224-35.
2. Bhattacharjee AK, Cross AS. Vaccines and antibodies in the prevention and treatment of sepsis. Infect Dis Clin North Am 1999; 13: 355-69.
3. Abraham E. Cytokine neutralization. In: Marschall JC, Cohen J (eds) Immune response in the critically ill. Springer, Heidelberg 2000: 385-92.
4. Calandra T. Pathogenesis of septic shock: implications for prevention and treatment. J Chemother 2001; 13: 173-80.
5. Houdijk AP, Meijer C, Cuesta MA, Meyer S, van Leeuwen PAM. Perioperative anti-endotoxin strategies. Scand J Gastroenterol 1997; Suppl 222: 93-7.
6. Kox WJ, Volk T, Kox SN, Volk HD. Immunomodulatory therapies in sepsis. Intensive Care Med 2000; 26 Suppl 1: S124-8.
7. Kruzel ML, Harari Y, Mailman D, Actor JK, Zimecki M. Differential effects of prophylactic, concurrent and therapeutic lactoferrin treatment on LPS-induced inflammatory responses in mice. Clin Exp Immunol 2002; 130: 25-31.
8. Muchamuel T, Menon S, Pisacane P, Howard MC, Cockayne DA. IL-13 protects mice from lipopolysaccharide-induced lethal endotoxemia: correlation with down-modulation of TNF-α, IFN-γ and IL-12 production. J Immunol 1997; 158: 2898-903.
9. Randow F, Sybre V, Meisel C, Krausch D, Zuckermann H, Platzer C et al. Mechanism of endotoxin desensitization: involvement of interleukin 10 and transforming growth factor beta. J Exp Med 1995; 181: 1887-92.
10. th World Congress on Trauma, Shock, Inflammation and Sepsis (Munich, 29.02-04.03.2000), Bologna: Monduzzi Editore, 2000: 221-5.
11. Zisman DA, Kunkel SL, Strieter RM, Gauldie J, Tsai W, Bramson J et al. Anti-interleukin-12 therapy protects mice in lethal endotoxemia but impairs bacterial clearance in murine Escherichia coli peritoneal sepsis. Shock 1997; 8: 349-56.
12. Hevel EA. Evidence that tumor necrosis factor has an important role in antibacterial resistance. J Immunol 1989; 143: 2894-9.
13. Schlag G, Redl H, Davies J, Scannon P. Protective effect of bactericidal/permeability-increasing protein (rBPI21) in baboon sepsis is related to its antibacterial, not antiendotoxin properties. Ann Surg 1999; 229: 262-71.
14. Zhao YX, Tarkowski A. Impact of interferon-gamma receptor deficiency on experimental Staphylococcus aureus septicemia and arthritis. J Immunol 1995; 155: 5736-42.
15. Van der Poll T, Marchant A, Keogh CV, Goldman M, Lowry SF. Interleukin-10 impairs host defense in murine pneumococcal pneumonia. J Infect Dis 1996; 174: 994-1000.
16. Levy O. Antimicrobial proteins and peptides of blood: templates for novel antimicrobial agents. Blood 2000; 96: 2664-72.
17. rd. The effects of lactoferrin on Gram-negative bacteria. Adv Exp Med Biol 1994; 357: 71-90.
18. Lönnerdal B, Iyer S. Lactoferrin: molecular structure and biological function. Ann Rev Nutr 1995; 15: 93-110.
19. Birgens HS, Hansen NE, Karle H, Kristenson LO. Receptor binding of lactoferrin by human monocytes. Br J Haematol 1983; 54: 383-91.
20. Hu WL, Mazurier J, Montreuil J, Spik G. Isolation and partial characterization of a lactoferrin receptor from mouse intestinal brush border. Biochemistry 1990; 29: 235-41.
21. [21 ] Mazurier J, Legrand D, Hu WL, Montruil J, Spik G. Expression of human lactotransferrin receptors in phytohemagglutinin-stimulated human peripheral blood lymphocytes. Isolation of the receptors by antiligand affinity chromatography. Eur J Biochem 1989; 179: 481-7.
22. Sato R, Inanami O, Tanaka Y, Takese M, Naito Y. Oral administration of bovine lactoferrin for treatment of intractable stomatitis in feline immunodeficiency virus (FIV)-positive and FIV-negative cats. Am J Vet Res 1996; 57: 1443-6.
23. Tomita M, Bellamy W, Takese M, Yamamuchi K, Wakabayashi H, Kawase KJ. Potent antibacterial peptides generated by pepsin digestion of bovine lactoferrin. Dairy Sci 1991; 74: 4137-42.
24. Wakabayashi H, Abe S, Okutomi T, Tansho S, Kawase K, Yamaguchi H. Cooperative anti-Candida effects of lactoferrin or its peptides in combination with azole antifungal agents. Microbiol Immunol 1996; 40: 821-5.
25. Bhimani RS, Vendrow Y, Furmanski P. Influence of lactoferrin feeding and injection against systemic staphylococcal infections in mice. J Appl Microbiol 1999; 86: 135-44.
26. Teraguchi S, Ozawa K, Yasuda S, Shin K, Fukowatasi Y, Shimamura S. The bacteriostatic effects of orally administered bovine lactoferrin on intestinal Enterobacteriaceae of SPF mice fed bovine milk. Biosci Biotech Biochim 1994; 58: 482-7.
27. Weinberg ED. Iron withholding: a defense against infection and neoplasia. Physiol Rew 1984; 64: 65-102.
28. Edde L, Hipolito RB, Hwang FF, Headon DR, Shalwitz RA, Sherman PM. Lactoferrin protects neonatal rats from gut-related systemic infection. Am J Physiol Gastrointest Liver Physiol 2001; 281: G1140-50.
29. 3rd. Antibacterial activity of lactoferrin and a pepsin-derived lactoferrin peptide fragment. Infect Immun 1993; 61: 719-28.
30. Elass-Rochard E, Roseanu A, Legrand D, Trif M, Salmon V, Motas C et al. Lactoferrin-lipopolysaccharide interaction: involvement of the 28-34 region of human lactoferrin in the high-affiinity binding to Escherichia coli O55B5 lipopolysaccharide. Biochem J 1995; 312: 839-45.
31. Elas-Rochard E, Legrand D, Salmon V, Roseanu A, Trif M, Tobias PS et al. Lactoferrin inhibits the endotoxin interaction with CD14 by competition with the lipopolysaccharide-binding protein. Infect Immun 1998; 66: 486-91.
32. Zagulski T, Lipiński P, Zagulska A, Broniarek S, Jarzabek Z. Lactoferrin can protect mice against lethal dose of Escherichia coli in experimental infection in vivo. Brit J Exp Pathol 1989; 70: 697-704.
33. Zagulski T, Lipiński P, Zagulska A, Jarzabek Z. Bovine lactoferrin protects mice against Escherichia coli: comparison of different ways of its application and effect of reticuloendothelial system blockade. An Sci Pap Rep 1997; 15: 183-93.
34. Zagulski T, Lipiński P, Zagulska A, Jarzabek Z. Antibacterial system generated by lactoferrin in mice in vivo is primarily a killing system. Int J Pathol 1998; 79: 117-23.
35. Espevik T, Nissen-Meyer J. A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor tumor necrosis factor from human monocytes. J Immunol Methods 1986; 95: 99-105.
36. Conlon PJ. A rapid biologic assay for the detection of interleukin 1. J Immunol 1983; 131: 1280-2.
37. Zimecki M, Spiegel K, Wlaszczyk A, Kübler A, Kruzel ML. Lactoferrin increases the output of neutrophil precursors and attenuates the spontaneous production of TNF-α and IL-6 by peripheral blood cells. Arch Immunol Ther Exp 1999; 47: 113-18.
38. Dalrymple SA, Slattery R, Aud DM, Krishna M, Lucian LA, Murray R. Interleukin-6 is required for a protective immune response to systemic Escherichia coli infection. Infect Immun 1996; 64: 3231-5.
39. Dalrymple SA, Lucian LA, Slattery R, McNeil T, Aud DM, Fuchino S et al. Interleukin 6-deficient mice are highly susceptible to Listeria monocytogenes infection: correlation with inefficient neutrophilia. Infect Immun 1995; 63: 2262-8.
40. Machnicki M, Zimecki M, Zagulski T. Lactoferrin regulates the release of tumor necrosis factor alpha and interleukin 6 in vivo. Int J Exp Pathol 1993; 74: 433-9.
41. Gregory SH, Sagnimeni AJ, Wing EJ. Bacteria in the bloodstream are trapped in the liver and killed by immigrating neutrophils. J Immunol 1996; 157: 2514-20.
42. Gregory SH, Cousens LP, van Rooijen N, Döpp EA, Carlos TM, Wing EJ. Complementary adhesion molecules promote neutrophil - Kuppfer cell interaction and the elimination of bacteria taken up by the liver. J Immunol 2002; 168: 308-15.
43. Miyauchi H, Hashimoto S, Nakajima M, Shinoda I, Fukawatari Y, Hayasawa H. Bovine lactoferrin stimulates the phagocytic activity of human neutrophils: identification of its active domain. Cell Immunol 1998; 187: 34-7.
44. Vogels MT, Cantoni L, Carelli M, Sironi M, Ghezzi P, van der Meer JW. Role of acute phase proteins in interleukin-1-induced nonspecific resistance to bacterial infections in mice. Antimicrob Agents Chemother 1993; 37: 2527-33.
45. Sallmann FR, Baveye-Descamps S, Pattus F, Salmon V, Branza N, Spik G et al. Porins OmpC and PhoE of Escherichia coli as specific cell-surface targets of human lactoferrin. Binding characteristics and biological effects. J Biol Chem 1999; 274: 16107-14.